Repros Therapeutics, Inc. (RPRX)

[exwannabe]

Re: Androxal and HbA1c levels

Obviously the DT2 concept came up after the last trial, so the failure to measure glycation in any manner was not an obvious error.

But why should they run a trial now do so? We have will results of the TIMES-2 trial (testosterone in DB2 and metabolic syndrome patients, double blind) in shortly that should throw some light on this subject. See those results first and decide where to go. If T doesn't look good there, they can forget Androxal via that route. If T does look good, RPRX can go back to the partners desk.

Given that testosterone is being used and tested in the indication and Androxal does look to be a potential improvement, it is not a scam (hptaxi's words) even if it does not yet meet your personal requirements for serious consideration investment wise.

That said, clearly RPRX needs Prol., and w/o such does not have the resources to develop Androgel anyway. So it's all kind of moot.